Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Stephen C. Bain*, Ofri Mosenzon, Rosario Arechavaleta, Pawel Bogdański, Abdurrahman Comlekci, Agostino Consoli, Chaicharn Deerochanawong, Kathleen Dungan, Maria C. Faingold, Michael E. Farkouh, Denise R. Franco, Jeppe Gram, Cristian Guja, Pankaj Joshi, Rachid Malek, Juan F. Merino-Torres, Michael A. Nauck, Sue D. Pedersen, Wayne H.H. Sheu, Robert J. SilverCees J. Tack, Nikhil Tandon, Ole K. Jeppesen, Mette Strange, Mette Thomsen, Mansoor Husain

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

152 Downloads (Pure)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab